Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Publikováno v:
European journal of cancer (Oxford, England : 1990). 145
Background Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly lo
Autor:
Luca Malorni, Dario Romagnoli, Francesca Galardi, Ilenia Migliaccio, Stephen Chia, Francesca De Luca, Giulia Boccalini, Martine Piccart, Amelia McCartney, William J. Gradishar, Martina Bonechi, Marta Pestrin, Karin Mattsson, Matteo Benelli, Angelo Di Leo, Chiara Biagioni, Gaia Schiavon, Laura Biganzoli, Mattias Bergqvist
Publikováno v:
European journal of cancer (Oxford, England : 1990). 114
Thymidine kinase 1 (TK1) plays a critical role in DNA synthesis and cell proliferation. Recent studies have shown potential for serum TK1 activity (sTKa) as a prognostic marker and indicator of early response to endocrine therapy in advanced breast c
Autor:
Wendy R. Parulekar, Bingshu E. Chen, Lois E. Shepherd, Joyce O'Shaughnessy, P Liedke, Kathrin Strasser-Weippl, Ravi Ramjeesingh, Gautam Sudan, Paul E. Goss
Publikováno v:
European journal of cancer (Oxford, England : 1990). 90
Background Histological subtype, (invasive ductal breast cancer (IDBC)/invasive lobular breast cancer (ILBC)), might be a marker for differential response to endocrine therapy in breast cancer. Methods Clinical trial MA.27 compared 5 years of adjuvan
Autor:
Seock-Ah Im, Se Hyun Kim, Tae Yong Kim, Ki Hyeong Lee, Soo Jung Lee, Ji-Yeon Kim, Young-Hyuck Im, Yeon Hee Park, Jee Hyun Kim, Kyung Hae Jung, Hye Sook Han, Sung-Bae Kim, Joohyuk Sohn, In Hae Park, Kyung-Hun Lee, Keun Seok Lee, Yee Soo Chae, Jin-Hee Ahn, Gun Min Kim
Publikováno v:
European journal of cancer (Oxford, England : 1990). 86
Background Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics. A recent
Autor:
Jalal Vakili, Christiane Jungels, Andrea Gombos, Ahmad Awada, Lieveke Ameye, Martine Piccart-Gebhart, Marianne Paesmans, Philippe Aftimos, Laura Polastro, Dominique de Valeriola, Alfino Buttice, Thierry Gil, Joanne van den Eerenbeemt
Publikováno v:
European journal of cancer (Oxford, England : 1990). 60
Background Eribulin is a non-taxane microtubule dynamics inhibitor that showed a survival benefit versus treatment of physician's choice in a phase III trial enrolling patients with metastatic breast cancer (MBC). Methods The E7389-G000-398 trial was
Autor:
Usama Bilal, Vinay Prasad
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(16)
Censoring is increasingly appreciated as a potential bias affecting estimates of progression free survival (PFS) in randomised trials. In this commentary, we explore the central assumption of censoring. Censored patients are considered no more or les
Publikováno v:
European journal of cancer (Oxford, England : 1990). 49(15)
The authors would like to thank Dr. Montemurro for his important comments. It is indeed important to shed light on our primary hypothesis and not ignore these results. Numerous reports have addressed the differences between lobular and ductal breast
Autor:
Mario Campone, Francis P. Arena, Tetiana Taran, Hope S. Rugo, Kathleen I. Pritchard, Shinzaburo Noguchi, Mona El-Hashimyt, Thomas Bachelot, Aurelia Héniquez, Louise Provencher, Barbara Pistilli, Lowell L. Hart, Martine Piccart, Ashok Panneerselvam, Gabriel N. Hortobagyi, Bohuslav Melichar, Tarek Sahmoud, Howard A. Burris, José Baselga, Ines Deleu, Mikhail Shtivelband, Michael Gnant
Publikováno v:
European journal of cancer, 49 (12
Background Everolimus (EVE; an inhibitor of mammalian target of rapamycin [mTOR]) enhances treatment options for postmenopausal women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast canc
Autor:
Valentina Nekljudova, Hans Tesch, Gunter von Minckwitz, Jörn Hilfrich, K. Schwedler, Serban-Dan Costa, Christine Mau, Peter A. Fasching, Jens-Uwe Blohmer, Petra Krabisch, Cornelia Höß, K Kittel, Jens Huober, Sherko Kümmel, Christian Jackisch, Holger Eidtmann, Michael Untch, F Khandan, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Sibylle Loibl
Publikováno v:
European journal of cancer (Oxford, England : 1990). 49(10)
Background We tested the oral mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to paclitaxel in patients with HER2-negative tumours not responding to initial neoadjuvant cytotoxic and anti-angiogenic treatment. Methods Patients w
Autor:
Kazuki Kishi, Yasuto Naoi, Seung Jin Kim, Atsushi Shimomura, Yasuhiro Tamaki, Shinzaburo Noguchi, Yousuke Baba, Takahiro Nakayama, Kenzo Shimazu, Hiroyuki Yasojima
Publikováno v:
European journal of cancer (Oxford, England : 1990). 47(12)
Background The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). Methods Tumour